MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 5.3% – Time to Sell?

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) traded down 5.3% during mid-day trading on Tuesday . The company traded as low as $16.55 and last traded at $16.4080. Approximately 560,651 shares were traded during mid-day trading, a decline of 62% from the average session volume of 1,463,796 shares. The stock had previously closed at $17.33.

Trending Headlines about MoonLake Immunotherapeutics

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: Strong Phase 3 psoriatic arthritis results: MoonLake reported that sonelokimab met all primary and secondary clinical goals in the Phase 3 IZAR-1 trial at Week 16. In the 60 mg induction group, 42.1% of patients achieved ACR50, while ACR20 reached 66.5%; among patients with skin involvement, 61% achieved PASI90 and 41.2% achieved minimal disease activity. The results support the drug’s potential in psoriatic arthritis and could strengthen its regulatory and commercial outlook. Reuters article
• Positive Sentiment: Improved financial result and ample liquidity: Second-quarter adjusted results included a loss of $0.84 per share, narrower than the $0.92 analyst consensus. MoonLake ended the quarter with $537 million in cash, cash equivalents and short-term marketable securities, expects its cash runway to extend through mid-2028, and said up to $400 million remains available under its Hercules Capital facility. MoonLake Q2 results article
• Positive Sentiment: Upcoming catalysts: MoonLake expects to complete IZAR-2 enrollment in the third quarter of 2026 and submit a biologics license application for sonelokimab in hidradenitis suppurativa by the end of September.
• Neutral Sentiment: Options activity increased: Traders purchased 2,707 call options, about 142% above typical daily volume, indicating heightened interest and potentially bullish speculation, though options activity does not confirm sustained buying in the shares.
• Neutral Sentiment: Analyst stance remains cautious: Brokerages give MLTX an average “Hold” recommendation, suggesting the positive trial data may already be partly reflected in valuation.
• Negative Sentiment: Ongoing losses and insider selling: MoonLake reported a $61.8 million quarterly net loss, including $50.2 million in research and development expenses. Separately, company insiders reportedly made no open-market purchases and sold shares in the past six months, which may weigh on investor sentiment.

Wall Street Analyst Weigh In

MLTX has been the topic of several recent research reports. Needham & Company LLC boosted their price target on MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Monday, July 20th. BTIG Research reissued a “buy” rating and set a $30.00 target price on shares of MoonLake Immunotherapeutics in a research report on Tuesday, June 9th. Weiss Ratings restated a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research note on Friday. Finally, Leerink Partners raised their price target on shares of MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the company an “outperform” rating in a report on Wednesday, July 1st. Ten equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $24.21.

MoonLake Immunotherapeutics Stock Down 6.4%

The firm has a fifty day simple moving average of $19.02 and a 200-day simple moving average of $17.89. The company has a market capitalization of $1.19 billion, a PE ratio of -4.20 and a beta of 1.06. The company has a debt-to-equity ratio of 0.39, a quick ratio of 8.60 and a current ratio of 8.60.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its earnings results on Monday, August 10th. The company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.08. Equities research analysts anticipate that MoonLake Immunotherapeutics will post -3.64 EPS for the current fiscal year.

Insider Buying and Selling at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, CEO Da Silva Jorge Santos sold 68,289 shares of the stock in a transaction on Friday, July 10th. The shares were sold at an average price of $20.02, for a total transaction of $1,367,145.78. Following the transaction, the chief executive officer directly owned 2,774,893 shares in the company, valued at $55,553,357.86. This represents a 2.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kristian Reich sold 50,000 shares of the firm’s stock in a transaction on Tuesday, July 21st. The stock was sold at an average price of $20.02, for a total transaction of $1,001,000.00. Following the transaction, the insider directly owned 2,714,746 shares of the company’s stock, valued at approximately $54,349,214.92. This represents a 1.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 344,800 shares of company stock worth $6,820,071 over the last ninety days. 10.40% of the stock is currently owned by corporate insiders.

Institutional Trading of MoonLake Immunotherapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Kestra Advisory Services LLC bought a new stake in MoonLake Immunotherapeutics in the fourth quarter valued at about $26,000. Bank of America Corp DE lifted its holdings in MoonLake Immunotherapeutics by 64.7% during the 3rd quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock worth $32,000 after buying an additional 1,781 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of MoonLake Immunotherapeutics by 115.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after acquiring an additional 3,166 shares in the last quarter. Russell Investments Group Ltd. grew its position in shares of MoonLake Immunotherapeutics by 45.4% in the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock worth $45,000 after acquiring an additional 1,069 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new stake in shares of MoonLake Immunotherapeutics in the 4th quarter valued at approximately $47,000. 93.85% of the stock is owned by institutional investors.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.